BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29266381)

  • 1. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.
    Sailer V; Schiffman MH; Kossai M; Cyrta J; Beg S; Sullivan B; Pua BB; Lee KS; Talenfeld AD; Nanus DM; Tagawa ST; Robinson BD; Rao RA; Pauli C; Bareja R; Beltran LS; Sigaras A; Eng KW; Elemento O; Sboner A; Rubin MA; Beltran H; Mosquera JM
    Cancer; 2018 Mar; 124(5):1008-1015. PubMed ID: 29266381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy.
    Van Allen EM; Foye A; Wagle N; Kim W; Carter SL; McKenna A; Simko JP; Garraway LA; Febbo PG
    Prostate Cancer Prostatic Dis; 2014 Mar; 17(1):23-7. PubMed ID: 24366412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.
    Beltran H; Yelensky R; Frampton GM; Park K; Downing SR; MacDonald TY; Jarosz M; Lipson D; Tagawa ST; Nanus DM; Stephens PJ; Mosquera JM; Cronin MT; Rubin MA
    Eur Urol; 2013 May; 63(5):920-6. PubMed ID: 22981675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimising CT-guided biopsies of sclerotic bone lesions in cancer patients.
    Donners R; Fotiadis N; Figueiredo I; Blackledge M; Westaby D; Guo C; Fenor de la Maza MLD; Koh DM; Tunariu N
    Eur Radiol; 2022 Oct; 32(10):6820-6829. PubMed ID: 35881184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
    Donners R; Figueiredo I; Westaby D; Koh DM; Tunariu N; Carreira S; de Bono JS; Fotiadis N
    Cancer Imaging; 2023 Dec; 23(1):121. PubMed ID: 38102655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies.
    Bins S; Cirkel GA; Gadellaa-Van Hooijdonk CG; Weeber F; Numan IJ; Bruggink AH; van Diest PJ; Willems SM; Veldhuis WB; van den Heuvel MM; de Knegt RJ; Koudijs MJ; van Werkhoven E; Mathijssen RH; Cuppen E; Sleijfer S; Schellens JH; Voest EE; Langenberg MH; de Jonge MJ; Steeghs N; Lolkema MP
    Oncologist; 2017 Jan; 22(1):33-40. PubMed ID: 27662884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report.
    Hongo H; Kosaka T; Aimono E; Nishihara H; Oya M
    Diagn Pathol; 2020 Jan; 15(1):5. PubMed ID: 31931827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment.
    Arnold RS; Fedewa SA; Goodman M; Osunkoya AO; Kissick HT; Morrissey C; True LD; Petros JA
    Bone; 2015 Sep; 78():81-6. PubMed ID: 25952970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.
    Robertson NL; Sala E; Benz M; Landa J; Scardino P; Scher HI; Hricak H; Vargas HA
    J Urol; 2017 Jul; 198(1):65-70. PubMed ID: 28216327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
    JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.
    Palapattu GS; Salami SS; Cani AK; Hovelson DH; Lazo de la Vega L; Vandenberg KR; Bratley JV; Liu CJ; Kunju LP; Montgomery JS; Morgan TM; Natarajan S; Huang J; Tomlins SA; Marks LS
    Clin Cancer Res; 2017 Feb; 23(4):985-991. PubMed ID: 28031426
    [No Abstract]   [Full Text] [Related]  

  • 13. Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging.
    Arita Y; Takahara T; Yoshida S; Kwee TC; Yajima S; Ishii C; Ishii R; Okuda S; Jinzaki M; Fujii Y
    Invest Radiol; 2019 Oct; 54(10):638-644. PubMed ID: 31192827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies.
    Cornud F; Roumiguié M; Barry de Longchamps N; Ploussard G; Bruguière E; Portalez D; Malavaud B
    Radiology; 2018 May; 287(2):534-542. PubMed ID: 29361246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
    Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
    J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield.
    Holmes MG; Foss E; Joseph G; Foye A; Beckett B; Motamedi D; Youngren J; Thomas GV; Huang J; Aggarwal R; Alumkal JJ; Beer TM; Small EJ; Link TM
    J Vasc Interv Radiol; 2017 Aug; 28(8):1073-1081.e1. PubMed ID: 28549709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation detection in formalin-fixed prostate cancer biopsies taken at the time of diagnosis using next-generation DNA sequencing.
    Manson-Bahr D; Ball R; Gundem G; Sethia K; Mills R; Rochester M; Goody V; Anderson E; O'Meara S; Flather M; Keeling M; Yazbek-Hanna M; Hurst R; Curley H; Clark J; Brewer DS; McDermott U; Cooper C
    J Clin Pathol; 2015 Mar; 68(3):212-7. PubMed ID: 25586381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prostate cancer diagnosed through the biopsy of the bone metastatic lesion; a case report].
    Ueda Y; Higuchii Y; Hashimoto T; Mitsui Y; Maruyamai T; Kondou N; Nojima M; Yamamoto S; Shincho M; Hirota S; Shima H
    Hinyokika Kiyo; 2007 May; 53(5):327-30. PubMed ID: 17561720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.
    Beer AJ; Schwarzenböck SM; Zantl N; Souvatzoglou M; Maurer T; Watzlowik P; Kessler H; Wester HJ; Schwaiger M; Krause BJ
    Oncotarget; 2016 May; 7(19):28151-9. PubMed ID: 27058620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.